利妥昔单抗联合高强度免疫化疗治疗散发性成人伯基特淋巴瘤的疗效与预后分析
该回顾性研究分析了2011年6月至2023年2月中国医学科学院血液病医院30例初诊散发性成人伯基特淋巴瘤患者,均接受利妥昔单抗联合高强度化疗诱导,客观缓解率80.0%、完全缓解率76.7%,5年无进展生存率和总生存率均为(76.7±7.7)%。BL-IPI高危组预后欠佳,诱导敏感的高危进展期患者序贯一线自体造血干细胞移植巩固可能进一步改善疗效。
要点
- 30例患者接受利妥昔单抗联合高强度化疗诱导,客观缓解率80.0%、完全缓解率76.7%。
- 中位随访49个月,5年无进展生存率和总生存率均为(76.7±7.7)%。
- BL-IPI低、中、高危组5年无进展生存率分别为(83.3±15.2)%、100.0%和(45.5±15.0)%(P=0.0069)。
核心结论
- 强烈免疫化疗方案对高度侵袭性成人伯基特淋巴瘤整体疗效和安全性良好,局限期患者疗效佳,BL-IPI高危患者预后欠佳。
- 诱导治疗敏感的高危、进展期患者序贯一线自体造血干细胞移植巩固治疗可能进一步改善疗效。
- BL-IPI评分≥2分、结外侵犯部位≥2个和诱导治疗未达首次完全缓解是成人伯基特淋巴瘤患者的预后不良因素。
研究设计与样本
- 回顾性研究,分析2011年6月至2023年2月在中国医学科学院血液病医院诊治的30例初诊伯基特淋巴瘤患者的临床和生存资料。
- 采用Kaplan-Meier法计算生存率,Log-rank检验进行预后因素单因素分析。
主要发现
- 30例患者中位年龄43(24~66)岁,男女比例3∶2;80.0%伴结外侵犯、53.3%伴骨髓侵犯、10.0%伴中枢神经系统侵犯,Ann Arbor分期Ⅲ~Ⅳ期占86.7%。
- BL-IPI低危(0分)、中危(1分)、高危(≥2分)者分别占20.0%、43.3%和36.7%。
- 所有患者接受利妥昔单抗联合高强度化疗诱导,客观缓解率80.0%、完全缓解率76.7%;中位随访49(6~153)个月,5年无进展生存率和总生存率均为(76.7±7.7)%。
- 4例局限期患者均获得持续完全缓解;10例对诱导敏感的高危进展期患者序贯一线自体造血干细胞移植巩固,除1例伴中枢神经系统侵犯者早期疾病进展死亡外,其余9例均获得持续完全缓解。
- BL-IPI低危、中危、高危组5年无进展生存率分别为(83.3±15.2)%、100.0%和(45.5±15.0)%(P=0.0069),总生存率分别为(83.3±15.2)%、100.0%和(45.5±15.0)%(P=0.0075);诱导期间主要不良反应为骨髓抑制和继发感染,均可对症处理。
关键数值与推荐
- 单因素分析显示,结外侵犯部位≥2个与更短无进展生存相关(HR=12.62,95% CI 2.59~61.62,P=0.0021)。
- 单因素分析显示,BL-IPI评分≥2分与更短无进展生存相关(HR=4.90,95% CI 1.02~23.45,P=0.0329)。
- 单因素分析显示,诱导治疗未达首次完全缓解与更短无进展生存相关(HR=31.86,95% CI 4.19~242.20,P<0.0001)。
临床怎么用
- 作者认为,强烈免疫化疗方案对成人伯基特淋巴瘤整体疗效和安全性良好,局限期患者疗效佳。
- 作者认为,诱导治疗敏感的高危、进展期患者序贯一线自体造血干细胞移植巩固治疗可能进一步改善疗效。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To explore the therapeutic efficacy and prognostic factors of combined rituximab and intensive chemotherapy for sporadic adult Burkitt lymphoma (BL) . Methods: This retrospective study examined the clinical and survival data of 30 patients newly diagnosed with BL between July 2011 and February 2023 at the Blood Diseases Hospital. Kaplan-Meier method was used for survival analysis, and the log-rank test was used for univariate analysis of prognostic factors. Results: The median age of the 30 patients was 43 years (24 - 66 years), and the male to female ratio was 3: 2. Extranodal invasion was present in 80% of the patients, with involvement of the bone marrow in 53.3% and central nervous system in 10.0%. The Ann Arbor stage was Ⅲ and Ⅳ in 86.7%. According to the number of Burkitt Lymphoma International Prognostic Index (BL-IPI) risk factors, patients were classified as low risk (0) in 20.0%, intermediate risk (1) in 43.3%, and high risk (≥2) in 36.7%. All patients were treated with an induction regimen of rituximab combined with intensive chemotherapy, with objective and complete response rates of 80.0% and 76.7%, respectively. The median follow-up was 49 months (6-153 months), and the 5-year progression-free survival (PFS) and overall survival (OS) rates were both (76.7±7.7) %. All patients with limited stage (n=4) achieved continuous complete remission (CCR). Patients who had high risk, advanced stage sensitive to induction therapy (n=10) sequentially received first-line autologous hematopoietic stem cell transplantation (auto-HSCT) as consolidation therapy; 9 patients achieved CCR, whereas 1 patient with central nervous system invasion developed early disease progression and died. The BL-IPI low, intermediate, and high risk groups had respective 5-year PFS rates of (83.3±15.2) %, 100.0%, and (45.5±15.0) % (P=0.0069) and OS rates of (83.3±15.2) %, 100.0%, and (45.5±15.0) % (P=0.0075). The main adverse effects of induction therapy were myelosuppression and secondary infections, which were effectively managed by appropriate symptomatic treatment. Univariate analysis demonstrated that worse PFS was associated with BL-IPI score ≥2 (HR=4.90, 95% CI 1.02-23.45, P=0.0329) ; extranodal invasion at ≥2 sites (HR=12.62, 95% CI 2.59-61.62, P=0.0021) ; and failure to achieve first complete response (CR1) after induction therapy (HR=31.86, 95% CI 4.19-242.20, P<0.0001) . Conclusions: Intensive immunochemotherapy regimens were effective and well-tolerated by adult patients with highly aggressive BL. Treatment efficacy was ideal in patients with limited-stage disease, whereas prognosis was unsatisfactory in patients with high-risk BL-IPI. Sequential first-line auto-HSCT consolidation therapy may further improve outcomes in patients with high-risk advanced-stage disease who are sensitive to induction therapy. BL-IPI score ≥2, extranodal invasion at ≥2 sites, and failure to achieve CR1 after induction therapy were adverse prognostic factors in adult patients with BL. 目的: 探讨利妥昔单抗联合高强度化疗治疗散发性成人伯基特淋巴瘤(BL)的治疗效果及预后因素。 方法: 回顾性分析2011年6月至2023年2月在中国医学科学院血液病医院诊治的30例初诊BL患者的临床和生存信息,采用Kaplan-Meier法计算生存率,运用Log-rank检验对预后因素进行单因素分析。 结果: 30例患者的中位年龄为43(24~66)岁,男女比例为3∶2。80.0%患者伴结外侵犯、53.3%伴骨髓侵犯、10.0%伴中枢神经系统侵犯,Ann Arbor分期Ⅲ~Ⅳ期占86.7%。伯基特淋巴瘤国际预后指数(BL-IPI)评分为低危(0分)、中危(1分)和高危(≥2分)者分别占比20.0%、43.3%和36.7%。所有患者均接受利妥昔单抗联合高强度化疗作为初始诱导治疗方案,客观缓解率和完全缓解率分别为80.0%和76.7%。中位随访时间为49(6~153)个月,5年的无进展生存(PFS)率和总生存(OS)率均为(76.7±7.7)%。4例局限期患者均获得持续的完全缓解(CCR)。10例对诱导治疗敏感的高危、进展期患者序贯一线auto-HSCT巩固治疗,除1例伴中枢神经系统侵犯的患者发生早期疾病进展而死亡,其余9例均获得CCR。BL-IPI低危、中危和高危组患者的5年PFS率分别为(83.3±15.2)%、100.0%和(45.5±15.0)%(P=0.0069),OS率分别为(83.3±15.2)%、100.0%和(45.5±15.0)%(P=0.0075)。诱导治疗期间的主要不良反应为骨髓抑制和继发感染,但均可对症处理。单因素分析显示,结外侵犯部位≥ 2个(HR=4.90,95% CI 1.02~23.45,P=0.0329)、BL-IPI评分≥2分(HR=12.62,95% CI 2.59~61.62,P=0.0021)和诱导治疗未达首次完全缓解(CR1)(HR=31.86,95% CI 4.19~242.20,P<0.0001)与更短的PFS期相关。 结论: 成人BL具有高度侵袭性,强烈免疫化疗方案整体上具有良好的疗效和安全性。局限期患者疗效佳,BL-IPI高危患者预后欠佳。诱导治疗敏感的高危、进展期患者序贯一线auto-HSCT巩固治疗可能进一步改善疗效。BL-IPI评分≥2分、结外侵犯部位≥2个和诱导治疗未达CR1是成人BL患者的预后不良因素。.
引用
- Dong CM, Zou HS, Zhang W, et al. [Rituximab combined with intensive immunochemotherapy for sporadic adult Burkitt lymphoma: efficacy and prognosis analyse]. Zhonghua Xue Ye Xue Za Zhi. 2025. PMID: 40134195. doi:10.3760/cma.j.cn121090-20241130-00505
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。